A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

Chronic Hand Eczema Clinical Trial

Official title:

A 24 Week, Randomised, Assessor Blinded, Active-controlled, Parallel Group, Phase 3, 2 Arm Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05259722
• Other study ID #: LP0133-1528
• Secondary ID: 2021-003543-16
• Status: Completed
• Phase: Phase 3
• Start date: June 15, 2022
• Est. completion date: December 5, 2023

Study information

• Verified date: April 2024
• Source: LEO Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable. Eligible participants will be randomised to receive topical administration of delgocitinib cream 20 mg/g, twice-daily, or oral administration of alitretinoin capsules 30 mg (with an option to reduce to 10 mg during trial conduct), once-daily. The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. The purpose of this trial is to compare the efficacy, health-related quality of life, and safety of delgocitinib cream and alitretinoin capsules.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 513
• Est. completion date: December 5, 2023
• Est. primary completion date: November 8, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Main inclusion criteria:

• Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
• Disease severity graded as severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 4).
• Participants who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
• Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.
• Participants must use contraceptive methods in accordance with local regulations regarding the methods of contraception for those participating in clinical studies

Main exclusion criteria:

• Concurrent skin diseases on the hands, e.g. tinea manuum.
• Active atopic dermatitis requiring medical treatment in regions other than the hands and feet.
• Active psoriasis on any part of the body.
• Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
• Clinically significant infection on the hands.
• Participants who cannot receive alitretinoin.
• Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial.
• History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
• Any disorder which is not stable and could:
• Affect the safety of the participant throughout the trial.
• Impede the participant's ability to complete the trial.
• Positive hepatitis B surface antigen or hepatitis C virus antibody serology at screening.
• Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline.
• Use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline.
• Previous or current treatment with Janus kinase (JAK) inhibitors (including delgocitinib/LEO 124249), systemic or topical.
• Cutaneously applied treatment with immunomodulators or TCS on the hands within 14 days prior to baseline.
• Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
• Other transdermal or cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 7 days prior to baseline.
• Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
• Treatment with any marketed biological therapy or investigational biologic agents:
• Any cell-depleting agents: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
• Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
• Previously used alitretinoin or participated in a clinical trial with alitretinoin or delgocitinib.

Related Conditions & MeSH terms

• Chronic Hand Eczema
• Eczema

Intervention

Drug:
• Delgocitinib
Cream for topical application 20 mg/g
• Toctino
1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur

Locations

Country	Name	City	State
Austria	LEO Pharma Investigational Site	Graz
Austria	LEO Pharma Investigational Site	Linz
Austria	LEO Pharma Investigational Site	Linz
Canada	LEO Pharma Investigational Site	Calgary
Canada	LEO Pharma Investigational Site	Calgary
Canada	LEO Pharma Investigational Site	Edmonton
Canada	LEO Pharma Investigational Site	Edmonton
Canada	LEO Pharma Investigational Site	Guelph
Canada	LEO Pharma Investigational Site	London
Canada	LEO Pharma investigational site	London
Canada	LEO Pharma investigational site	Markham
Canada	LEO Pharma investigational site	Niagara Falls
Canada	LEO Pharma Investigational Site	North York
Canada	LEO Pharma investigational site	Québec
Canada	LEO Pharma Investigational Site	Red Deer
Canada	LEO Pharma investigational site	Sherbrooke
France	LEO Pharma Investigational Site	Antony
France	LEO Pharma Investigational Site	Martigues
France	LEO Pharma Investigational Site	Montpellier
France	LEO Pharma Investigational Site	Nice
France	LEO Pharma investigational site	Nice
France	LEO Pharma Investigational Site	Reims
France	LEO Pharma Investigational Site	Toulon
Germany	LEO Pharma Investigational Site	Augsburg
Germany	LEO Pharma Investigational Site	Berlin
Germany	LEO Pharma Investigational Site	Berlin
Germany	LEO Pharma Investigational Site	Bochum
Germany	LEO Pharma Investigational Site	Bochum
Germany	LEO Pharma Investigational Site	Bonn
Germany	LEO Pharma Investigational Site	Darmstadt
Germany	LEO Pharma Investigational Site	Dresden
Germany	LEO Pharma Investigational Site	Erlangen
Germany	LEO Pharma Investigational Site	Essen
Germany	LEO Pharma Investigational Site	Frankfurt
Germany	LEO Pharma Investigational Site	Friedrichshafen
Germany	LEO Pharma Investigational Site	Gera
Germany	LEO Pharma Investigational Site	Göttingen
Germany	LEO Pharma Investigational Site	Halle
Germany	LEO Pharma Investigational Site	Hamburg
Germany	LEO Pharma Investigational Site	Heidelberg
Germany	LEO Pharma Investigational Site	Langenau
Germany	LEO Pharma Investigational Site	Lohne
Germany	LEO Pharma Investigational Site	Mainz
Germany	LEO Pharma Investigational Site	Marburg
Germany	LEO Pharma Investigational Site	Memmingen
Germany	LEO Pharma Investigational Site	München
Germany	LEO Pharma Investigational Site	München
Germany	LEO Pharma Investigational Site	Oldenburg
Germany	LEO Pharma Investigational Site	Osnabrück
Germany	LEO Pharma Investigational Site	Wuppertal
Italy	LEO Pharma Investigational Site	Bologna
Italy	LEO Pharma Investigational Site	Brescia
Italy	LEO Pharma Investigational Site	Catania
Italy	LEO Pharma Investigational Site	Catanzaro
Italy	LEO Pharma Investigational Site	Genova
Italy	LEO Pharma Investigational Site	Lucca
Italy	LEO Pharma Investigational Site	Milano
Italy	LEO Pharma Investigational Site	Pavia
Italy	LEO Pharma Investigational Site	Pisa
Italy	LEO Pharma Investigational Site	Terracina
Norway	LEO Pharma Investigational Site	Stavanger
Norway	LEO Pharma Investigational Site	Tromsø
Poland	LEO Pharma Investigational Site	Bialystok
Poland	LEO Pharma investigational site	Bydgoszcz
Poland	LEO Pharma Investigational Site	Chorzów
Poland	LEO Pharma Investigational Site	Gdansk
Poland	LEO Pharma Investigational Site	Gdynia
Poland	LEO Pharma Investigational Site	Katowice
Poland	LEO Pharma investigational site	Katowice
Poland	LEO Pharma investigational site	Katowice
Poland	LEO Pharma Investigational Site	Kraków
Poland	LEO Pharma Investigational Site	Kraków
Poland	LEO Pharma Investigational Site	Kraków
Poland	LEO Pharma Investigational Site	Lódz
Poland	LEO Pharma Investigational Site	Lublin
Poland	LEO Pharma Investigational Site	Poznan
Poland	LEO Pharma Investigational Site	Strzelce Opolskie
Poland	LEO Pharma Investigational Site	Szczecin
Poland	LEO Pharma Investigational Site	Warszawa
Poland	LEO Pharma Investigational Site	Wroclaw
Slovakia	LEO Pharma Investigational Site	Bratislava
Slovakia	LEO Pharma Investigational Site	Svidník
Slovakia	LEO Pharma Investigational Site	Trnava
Spain	LEO Pharma Investigational Site	Alcalá de Henares
Spain	LEO Pharma Investigational Site	Alicante
Spain	LEO Pharma Investigational Site	Badalona
Spain	LEO Pharma Investigational Site	Barcelona
Spain	LEO Pharma Investigational Site	Barcelona
Spain	LEO Pharma Investigational Site	Córdoba
Spain	LEO Pharma Investigational Site	Hospitalet de Llobregat
Spain	LEO Pharma Investigational Site	Madrid
Spain	LEO Pharma Investigational Site	Madrid
Spain	LEO Pharma Investigational Site	Madrid
Spain	LEO Pharma Investigational Site	Madrid
Spain	LEO Pharma investigational site	Málaga
Spain	LEO Pharma investigational site	Pontevedra
Spain	LEO Pharma Investigational Site	Sevilla
Spain	LEO Pharma Investigational Site	Valencia
Spain	LEO Pharma Investigational Site	Valencia
Spain	LEO Pharma Investigational Site	Zaragoza
United Kingdom	LEO Pharma Investigational Site	London
United Kingdom	LEO Pharma Investigational Site	Nottingham

Sponsors (1)

Lead Sponsor	Collaborator
LEO Pharma

Countries where clinical trial is conducted

Austria,  Canada,  France,  Germany,  Italy,  Norway,  Poland,  Slovakia,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in HECSI score from baseline to Week 12	The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).	12 weeks
Secondary	HECSI-90 at Week 12	The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.	12 weeks
Secondary	IGA-CHE TS at Week 12.	The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a =2-step improvement from baseline.	12 weeks
Secondary	Change in HESD itch score (weekly average) from baseline to Week 12	The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.	12 weeks
Secondary	Change in HESD pain score (weekly average) from baseline to Week 12.	The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.	12 weeks
Secondary	AUC of HECSI-90 from baseline up to Week 24	The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. The area under the curve (AUC) at participant level will be determined as follows: 1 will be assigned when response is observed and 0 otherwise. The AUC is interpreted as number of days with 90% reduction in HECSI score until Week 24.	24 weeks
Secondary	AUC of change from baseline in DLQI score up to Week 24	The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30). The area under the curve (AUC) at patient level will be determined from the change from baseline in DLQI score estimated piecewise from Week 0 to Week 24. Differences will be analysed with opposite sign to interpret positive area as improvement in scores and negative area as worsening.	24 weeks
Secondary	Change in HECSI score from baseline to Week 24	The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).	24 weeks
Secondary	Number of treatment-emergent AEs from baseline up to Week 26	An adverse event (AE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.	26 weeks
Secondary	Number of treatment-emergent SAEs from baseline up to Week 26	A serious adverse event (SAE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.	26 weeks
Secondary	Number of AEs leading to IMP discontinuation up to Week 24	The investigational medicinal product (IMP) will be discontinued permanently in case of an AE that, in the opinion of the investigator or sponsor's medical expert, contraindicates further dosing. The investigator will assess the relationship between investigational medicinal product (IMP) and the adverse event (AE).	24 weeks